Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754877 | 0.90 | POLB (0.65) | ALDH1A1L3MBTL1TP53TSHRCYP1A2 | |
| SCHEMBL8708567 | 0.84 | ALDH1A1 (0.69) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL6001770 | 0.81 | ALDH1A1 (0.77) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL6001774 | 0.81 | ALDH1A1 (0.77) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL10852085 | 0.81 | ALDH1A1 (0.82) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL1494291 | 0.79 | ALDH1A1 (0.79) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL1063240 | 0.79 | HDAC3 (0.74) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL2092853 | 0.78 | ALDH1A1 (0.82) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL2092856 | 0.78 | ALDH1A1 (0.82) | ALDH1A1MAPTNPC1RAB9AHPGD | |
| SCHEMBL7370090 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTNPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | claimed |
| US-8163803-B2 | less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance | Fundação Oswaldo Cruz—FIOCRUZ (BR) | 2012-04-24 | — | — | US | disclosed |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | LTA, LCT, LTC4S | ALDH1A1 1601/4885MAPT 389/4885NPC1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.